FDA Clearance Tracker · P130013-S059
WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device with Delivery System
Last checked: Nov 20, 2026Latest source record: Oct 31, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Oct 31, 2023
Approved
Time to decision
41 days
Received Sep 20, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P130013-S059
- Device name
- WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device with Delivery System
- Applicant
- Boston Scientific Corp
- Applicant location
- Maple Grove, MN
- Received
- Sep 20, 2023
- Decided
- Oct 31, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P130013
Device type
- Device type
- System, appendage closure, left atrial (NGV)
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval of the protocol (amended via email on October 26, 2023) for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P130013/S057.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.